Infex Therapeutics Advances RESP-X Toward Next-Stage Development
ALDERLEY PARK, Cheshire, U.K. — September 8, 2026 Infex Therapeutics presented new data from its Phase IIa study of...
Non-Cystic Fibrosis Bronchiectasis
Advertisement
Insmed Presents New ARIKAYCE Data From Phase 3b ENCORE
Bridgewater, New Jersey, USA, September 3, 2026 Insmed Incorporated announced that five abstracts from its respiratory portfolio have been...
Revagenix Doses First Patient in Phase 1 Rev-56 Trial
SAN FRANCISCO, Calif., July 27, 2026 Revagenix, Inc. announced that the first participant has been dosed in the Phase...
Infex Therapeutics Reports Positive Phase IIa RESP-X Data in Bronchiectasis
Alderley Park, Cheshire, U.K., May 21, 2026 Infex Therapeutics announced positive Phase IIa clinical trial results for RESP-X (INFEX702)...
Advertisement
